Allergan plc provided earnings guidance for the first quarter ending March 31, 2019 and full year ending December 31, 2019. For the first quarter ending March 31, 2019, the company expects GAAP total net revenues to be in the range of $3.40 billion to $3.55 billion and net loss per share to be in the range of $0.39 to $0.20.

For the full year ending December 31, 2019, the company expects GAAP total net revenues to be in the range of $15.0 billion to $15.30 billion and net income per share of less than or equal to $1.14.

In the fourth quarter of 2018, the company recorded total pre-tax impairment charges of $5.4 billion. This amount reflects $1.9 billion of other intangible asset impairments, including $1.6 billion for KYBELLA®/BELKYRA® as sales forecasts have declined. The Company's intended sale of Anti-Infectives and its increased cost of capital based on market dynamics as well as other commercial factors prompted a review of its General Medicine Reporting Unit goodwill. As a result, the Company wrote off $3.5 billion of total goodwill, including $622 million allocated to Anti-Infectives.